Review: The role of microglia in diabetic retinopathy and its potential as a therapeutic target.

IF 1.4 3区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular Vision Pub Date : 2026-02-07 eCollection Date: 2026-01-01

Wen Liu, Jieyu Jiang, Wenwen Li, Zhiming Liu, Xiangdong Chen

{"title":"Review: The role of microglia in diabetic retinopathy and its potential as a therapeutic target.","authors":"Wen Liu, Jieyu Jiang, Wenwen Li, Zhiming Liu, Xiangdong Chen","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetic retinopathy (DR) is a common and severe complication of diabetes, which poses a serious threat to vision, and its pathogenesis is complex. Inflammatory response plays a crucial role in the progression of DR, but currently, anti-vascular endothelial growth factor therapy, the preferred treatment for DR, only targets the vascular part. Therefore, determining a treatment method targeting the inflammatory response in DR is an important step in addressing DR. As immune cells within the retina, microglia play a key role in the inflammatory response in DR, which is a crucial link in its pathogenic mechanism. By regulating the inflammatory response of microglia, the progression of DR can be effectively slowed down. This review deeply explores the mechanism of action of microglia in DR by reviewing relevant research achievements and evaluates the potential of treatment strategies targeting microglia in slowing down the progression of DR. The study focuses on how to further optimize the treatment regimen for DR by regulating different pathways such as the release of inflammatory factors, the occurrence of oxidative stress, phenotypic transformation, intercellular interactions, and phagocytic activity of microglia, providing important clues for the development of novel treatment methods for DR. Through a comprehensive analysis and evaluation of the effectiveness and safety of these treatment strategies, the study aims to provide more precise and effective treatment regimens for patients with DR, so as to improve their visual prognosis and quality of life.</p>","PeriodicalId":18866,"journal":{"name":"Molecular Vision","volume":"32 ","pages":"49-68"},"PeriodicalIF":1.4000,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13056012/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Vision","FirstCategoryId":"3","ListUrlMain":"","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Diabetic retinopathy (DR) is a common and severe complication of diabetes, which poses a serious threat to vision, and its pathogenesis is complex. Inflammatory response plays a crucial role in the progression of DR, but currently, anti-vascular endothelial growth factor therapy, the preferred treatment for DR, only targets the vascular part. Therefore, determining a treatment method targeting the inflammatory response in DR is an important step in addressing DR. As immune cells within the retina, microglia play a key role in the inflammatory response in DR, which is a crucial link in its pathogenic mechanism. By regulating the inflammatory response of microglia, the progression of DR can be effectively slowed down. This review deeply explores the mechanism of action of microglia in DR by reviewing relevant research achievements and evaluates the potential of treatment strategies targeting microglia in slowing down the progression of DR. The study focuses on how to further optimize the treatment regimen for DR by regulating different pathways such as the release of inflammatory factors, the occurrence of oxidative stress, phenotypic transformation, intercellular interactions, and phagocytic activity of microglia, providing important clues for the development of novel treatment methods for DR. Through a comprehensive analysis and evaluation of the effectiveness and safety of these treatment strategies, the study aims to provide more precise and effective treatment regimens for patients with DR, so as to improve their visual prognosis and quality of life.

本刊更多论文

综述：小胶质细胞在糖尿病视网膜病变中的作用及其作为治疗靶点的潜力。

糖尿病视网膜病变（DR）是糖尿病常见且严重的并发症，严重威胁视力，其发病机制复杂。炎症反应在DR的进展中起着至关重要的作用，但目前DR首选的抗血管内皮生长因子治疗仅针对血管部分。因此，确定针对DR炎症反应的治疗方法是解决DR的重要一步，小胶质细胞作为视网膜内的免疫细胞，在DR炎症反应中起着关键作用，是其致病机制的关键环节。通过调节小胶质细胞的炎症反应，可以有效减缓DR的进展。本文通过对相关研究成果的回顾，深入探讨了小胶质细胞在DR中的作用机制，并评价了针对小胶质细胞的治疗策略在减缓DR进展中的潜力，重点研究如何通过调节炎症因子的释放、氧化应激的发生、表型转化、细胞间相互作用、本研究旨在通过对这些治疗策略的有效性和安全性进行综合分析和评价，为DR患者提供更精准有效的治疗方案，从而改善患者的视觉预后和生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Vision 生物-生化与分子生物学

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Molecular Vision is a peer-reviewed journal dedicated to the dissemination of research results in molecular biology, cell biology, and the genetics of the visual system (ocular and cortical). Molecular Vision publishes articles presenting original research that has not previously been published and comprehensive articles reviewing the current status of a particular field or topic. Submissions to Molecular Vision are subjected to rigorous peer review. Molecular Vision does NOT publish preprints. For authors, Molecular Vision provides a rapid means of communicating important results. Access to Molecular Vision is free and unrestricted, allowing the widest possible audience for your article. Digital publishing allows you to use color images freely (and without fees). Additionally, you may publish animations, sounds, or other supplementary information that clarifies or supports your article. Each of the authors of an article may also list an electronic mail address (which will be updated upon request) to give interested readers easy access to authors.